AIM
MGNX icon

Alambic Investment Management’s MacroGenics MGNX Stock Holding History

Alambic Investment Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-8,532
Closed -$215K – 407
2018
Q1 		$215K Buy
+8,532
New +$207K 0.03% 408

Other funds holding MGNX

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alambic Investment Management's MGNX Position: Q2 2018 in Review

Alambic Investment Management sold out of MacroGenics (MGNX) in Q2 2018, closing a stake of 8,532 shares — an estimated $215K sold.

Alambic Investment Management first reported a position in MGNX in Q1 2018 and held it in 1 quarter. The position peaked at $215K in Q1 2018. 127 funds tracked by Wall St. Rank hold MGNX as of Q2 2018.

  • Alambic Investment Management reported no remaining MacroGenics position as of Q2 2018 after selling out during the quarter.
  • Alambic Investment Management sold 8,532 MacroGenics shares in Q2 2018, an estimated $215K.
  • Alambic Investment Management first reported a position in MacroGenics in Q1 2018 and held it in 1 quarter.
  • Alambic Investment Management's MacroGenics position peaked at $215K in Q1 2018.
  • 127 funds tracked by Wall St. Rank held MacroGenics as of Q2 2018.

Based on Alambic Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.